Type 1 and type 2 diabetes both accelerate cardiovascular disease, yet the triggers are likely different for the two types of diabetes. Results from large-scale clinical trials suggest that intense blood glucose control can reduce cardiovascular events many years later in patients with type 1 diabetes. In type 2 diabetes, mechanisms related to insulin resistance and obesity may be more prominent in promoting atherosclerosis. In this article, we discuss the potential effects of hyperglycemia and diabetes-induced lipid abnormalities on atherosclerosis, particularly focusing on advanced stages of atherosclerosis and evidence from mouse models. In addition, we discuss new research fi ndings in monocyte/macrophage biology that may present intriguing new areas of research related to diabetes and atherosclerosis.
Introduction
Both type 1 and type 2 diabetes are associated with an increased risk of stroke, coronary heart disease, and peripheral arterial disease [1] . The underlying cause for many of these macrovascular complications is atherosclerosis. Rupture of advanced atherosclerotic lesions is the main culprit of cardiovascular events. The mechanisms related to accelerated atherosclerosis formation in diabetes are not well understood, yet many theories implicate both hyperglycemia and lipid abnormalities. Other factors, such as hypertension, smoking, and nephropathy, are also likely to play important roles, when present, as they do in patients without diabetes. Type 2 diabetes is generally associated with obesity and hyperlipidemia, whereas type 1 diabetes exhibits no detectable or modest lipid abnormalities [2] . Several large-scale clinical trials support an association between improved glucose control in type 1 diabetes and reduced cardiovascular-related events [3, 4] . The role of glycemic control in atherosclerosis associated with type 2 diabetes is not prominent, and new theories propose that lipid deposition precedes insulin resistance in most obesity-related diabetes, and that glucose's effects may be masked by those of lipid abnormalities [2, 5] . Accordingly, no direct evidence exists to suggest intense glucose control signifi cantly reduces cardiovascular-related events associated with type 2 diabetes [6, 7] . Therefore, a general effect of hyperglycemia in directly promoting cardiovascular events in diabetes is by no means well established, despite several clinical studies and many interesting in vitro observations. Furthermore, it is becoming increasingly clear that the mechanisms governing lesion initiation and those causing progression to advanced lesions are quite different.
This article addresses the concepts that hyperglycemia may play a role in promoting the early stages of atherosclerosis in type 1 diabetes, and that it is diffi cult to distinguish the effect of glucose from that of lipids in advanced atherosclerosis acceleration. In addition, this article addresses some of the exciting new advancements in monocyte/macrophage biology and suggests potential areas of focus for deciphering the effects of diabetes on infl ammation and atherosclerosis.
Animal Models of Diabetes-Accelerated Plaque Disruption and Cardiovascular Events Are Urgently Needed
Animal models have proven valuable as a means to investigate specifi c mechanisms involved in the atherosclerotic disease processes. However, most studies of atherosclerosis in animals with or without diabetes are derived from models of early lesion formation [8••,9] . This is in contrast to clinically relevant advanced human lesions, in which acute cardiovascular events precipitate from rupture of destabilized advanced plaques [10] . As yet, no one animal model exists that adequately models the processes of plaque rupture, thrombus formation, and occlusion of the lumen [9] . Therefore, there has been an effort to characterize the progression of advancing lesions in animal models, which has led to the identifi cation of surrogate markers for unstable plaques; most notable is intraplaque hemorrhage in the absence of plaque microvessels. Several groups have identifi ed models that present with intraplaque hemorrhage and other characteristics similar to advanced human disease. Gerrity et al. [11] identifi ed an appropriate phenotype in the coronary arteries of hyperlipidemic streptozotocin-diabetic swine. Our laboratory pioneered investigations into the effects of type 1 diabetes on advanced lesions using a low-density lipoprotein receptor defi cient (LDLR -/-) mouse model [12] . In this LDLR -/-type 1 diabetic mouse model, expression of the lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP) transgene is controlled by the insulin promoter. In this model (further referred to as the LDLR -/-;GP mouse model), type 1 diabetes can be induced by infection with LCMV, resulting in T-cell-mediated destruction of GP-expressing β cells, closely mimicking the autoimmune destruction of β cells seen in type 1 diabetes in humans. The defi ciency of the LDL receptor results in lipoprotein profi les that resemble human profi les (LDL and very low density lipoprotein [VLDL] enriched), which promotes atherosclerosis formation and progression. Importantly, advanced lesions with a disrupted phenotype are formed in the brachiocephalic artery (BCA) of these mice [12] . The BCA is a well-defi ned artery characterized by turbulent patterns of blood fl ow, which lead to formation of advanced plaques that reproducibly present with intraplaque hemorrhage [9] . The lesions at this site also exhibit other features characteristic of unstable human lesions, including thinning fi brous cap, necrotic core formation, calcifi cation, and the presence of infl ammatory cells [9] . We have shown that in the LDLR -/-;GP model, diabetes accelerates lesion initiation, measured as an increased macrophage accumulation and fatty streak formation in the BCA [12] . The effects of diabetes on lesion initiation were not dependent on differences in plasma lipid levels, and were most likely due to hyperglycemia or the consequences of hyperglycemia. Accordingly, intense insulin therapy normalized the diabetes-accelerated lesion initiation, thus confi rming that the accelerated lesion initiation was an effect of suboptimal metabolic control. However, in the setting of severe dyslipidemia, the effects of diabetes on atherosclerosis were masked [2, 12] .
Our laboratory recently conducted a study using the LDLR -/-;GP model to investigate the effect diabetes has on advanced, clinically more relevant lesions [8••] . The study's initial phase allowed advanced atherosclerotic lesions to form, and diabetes was induced after lesions developed into complex lesions with necrotic cores, fi brous caps, and beginning evidence of calcifi cation. In this study, the effects of diabetes on advance lesions, without confounding effects on lesion initiation, could therefore be investigated. Diabetes did not result in changes in lesion size but signifi cantly increased the presence of intraplaque hemorrhage and disruption of advanced BCA lesions [8••] . This suggests that diabetes can promote disruption of advanced lesions, potentially mimicking the process leading to cardiovascular-related events in humans with diabetes.
Is diabetes-induced plaque disruption due to glucose or lipids? Using a helper-dependent adenovirus we stably overexpressed the murine VLDL receptor in the liver of these mice, which markedly reduced VLDL and LDL levels in diabetic and nondiabetic mice without reducing hyperglycemia [8••] . Strikingly, aggressive lipid lowering corrected the appearance of intraplaque hemorrhage in diabetic mice, suggesting that VLDL/LDL are required for diabetes-induced plaque disruption, and that hyperglycemia alone is insuffi cient [8••] . Thus, our results identify VLDL/LDL as the culprit in disruption of lesions in type 1 diabetic mice, even though VLDL/LDL levels are not markedly affected by type 1 diabetes [12] . In early stages of lesion development, conversely, hyperglycemia is likely to promote lesion initiation [12] .
The results of the DCCT/EDIC (Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications) study suggest that strict blood glucose control has long-lasting benefi ts associated with reduced cardiovascular events in patients with type 1 diabetes years after the treatment period [4] . This phenomenon has been termed "metabolic memory." One possible explanation is that hyperglycemia may impact endothelial function early in lesion initiation, and that this could result in increased cardiovascular events years later. Hyperglycemia's effects may be less prominent in advanced lesions and in patients with hyperlipidemia. This hypothesis is consistent with the fi ndings that intense blood glucose control does not signifi cantly reduce cardiovascular-related events in type 2 diabetes, which is associated with hyperlipidemia that is likely to override hyperglycemia's relatively minor effects. This theory would suggest a greater need to focus on strict glucose control early in type 1 diabetes to reduce cardiovascular mortality, and additionally to focus on aggressive lipid lowering in type 2 diabetes and in later stages of type 1 diabetes. However, we would like to emphasize that hyperglycemia may promote thrombosis or other processes involved in cardiovascular events downstream of plaque disruption that are not well mimicked by the animal models currently available. Therefore, new animal models are urgently needed.
The Contributions of Glucose and Lipids Are Diffi cult to Distinguish
Prolonged hyperglycemia is often suggested to be the primary cause of diabetic complications, and thus has been the focus of most theories explaining the increase in macrovascular
